The health insurance companies (whether HEK / hkk participate in the respective lot depends on the name of the respective lot) pursue the goal of having discount agreements with all suitable pharmaceutical companies in accordance with Section 130a (8) of the Social Code Book V on the active substances, combinations of active substances or dosage forms, strengths close. The contract is concluded as part of the open house process:

Individual negotiations on contract content are not conducted, uniform conditions apply. The health insurance companies do not assure individual contracting partners exclusivity. The contract period is a maximum of 24 months starting from 1.9.2021 at the earliest (starting times for HEK and HKK may vary from the information provided in the corresponding lot). The contract ends no later than 31.8.2023, regardless of the date of conclusion of the contract. It is possible to join this open-house process at any time within the contract period. All further information can be found in the participation and contract documents.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.

The non-exclusive discount contracts concluded in the open house procedure of the health insurance funds basically serve to bridge the period between the expiry of a patent for active substances, combinations of active substances or dosage forms, strengths of action and the entry into force of exclusive discount contracts in accordance with Section 130a (8) SGB V. An accession to this Open house procedures are possible at any time within the contract period. A contract is concluded with all pharmaceutical companies who meet the requirements of the self-declaration on authorization and reliability contained in the procedural documents and who confirm this in text form in accordance with § 126b BGB. This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of providing the widest possible information to interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure name "Open Procedure" (Section IV.1.1)) used in the context of this announcement text and the specification of the award criteria (Section II.2.5)) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is not mandatory by law or award regulations.